Together, these data indicate that the inflammatory transcriptional signature related to NAFLD is abolished after timed NAD+ treatment, possibly through coordinating the action of transcription factors such as NFkB or FOXA2, and intracellular signaling involving the MTORC1 pathway. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.